| Title of Invention | A PROCESS FOR THE PRODUCTION OF A HIGHLY PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION |
|---|---|
| Abstract | The present invention relates to a process for the production of a highly palatable ductile chewable veterinary composition, comprising (i)feeding the hopper of an extruder with a composition comprising (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener and (E) up to 9% (w/w) of water, (ii)cooling constantly down the mixture of active ingredients and camera so that the temperature of the extrudate that leaves the tip of the extruder does during the whole extrusion process at no time exceed 40°C, (iii) pressing the extrudate through a die that is decisive for the shape of the chewable product, and (iv) cutting the extrudate that leaves the extruder into equal pieces. |
| Full Text | Palatable ductile chewable veterinary composition The present invention relates to an easy-to-use. safe, efficacious, and stable veterinary formulation consisting of a highly palatable ductile chewable veterinary composition comprising an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; of meat flavoring; of partially gelatinized starch; of a softener; and of up to 9% of water. The present invention also relates to a method of contorting said animal pests or pathogens and of curing or preventing said animal diseases by feeding an animal with said highly palatable ductile chewable veterinary composition. Further, ties invention relates to a process for producing said highly palatable ductile viewable veterinary composition by cold extrusion. In a preferred embodiment, the highly palatable ductile chewable veterinary composition controls animal pests like endow-parasites, such as worms, and simultaneously echo-parasites, such as biting insects like fleas, on pets. The pesticidaily effective ingredient is dispensed as the animal chews the product. Field and background of the invention Veterinary products can be administered to warm-blooded animals in very different ways depending on their mode of action and their ability to be taken up either by the treated animal or the target pest. Thus veterinary products can be administered, for example, torahs as pour-on or spot-on formulations, in form of shampoos, showers, as a dip. bath or spray, in form of a collar, and in many variants of these application forms. They can also be administered systemically, for example, orally, parent rally and in certain cases even transversally. Examples of systemic administration forms are: via injection, as a tablet, capsule, bolus, drink, feed additive and the like. Each of these administration forms can have advantages-ordisadvantages-depending-onthe-actdal-srtuation-andthe-animal-thatHsi need of such a treatment Treatment of herd animals, like horses, cater, sheep or poultry usually requires different administration methods than for the treatment of single animals, such as pets like dogs and cats. One very convenient and easy to manage administration form for human patients Is the oral uptake of a medicament. This would also be very desirable in the field of veterinary medicine but here the animal holder or veterinarian is confronted with the natural behavior of the animal and oral treatment can be a real challenge. Many attempts have been made to design the ideal oral application foci that is really accepted and voluntarily taken up by the animal but most of these application forms need still to be improved. The present inventors recognized that in the field of animal health the dosage form and epically the palatability of the dosage form, i.e. the natural acceptance of the drug plays the decisive role. The underlying problems are outlined hereinafter. While, in humans, medicaments may be administered in a wide variety of application formic, such as tablets, coated tablets, emulsions, injection solutions, suppositories and the Hoe, because the dispelling and the desire to recover in human patients can be ride upon, in the case of animals practical problems are soon encountered, since a few application forms, such as the usage of suppositories, either have to be dispensed with all together or other forms, such as injections, must only be carried out by the veterinarian. In general, humans do not like to visit the doctor. The same is true for animal keepers who would need advice from a veterinarian. In general, the animal keeper prefers to use those treatment methods that he can carry out himself without having involved a veterinarian. Among the preferred treatment methods, which an animal keeper can carry out himself, e.g. following the veterinarian's instructions, is the oral administration of medicaments. Treating humans with medicines is generally not problematic, because the human patient follows the advice of the doctor or reads the directions on the leaflet in the package and complies with them since this is in his own interest, and because the manufacturer usually prepares the tablet, capsule or coated tablet in a form which is appropriate for oral consumption-and- sateen-tailor d for human patient’s However, as soon as a pharmaceutical active ingredient has a taste which is unpleasant to the animal, whether because it is bitter or has some other unpleasant taste or is simply amen to the animal, the animal refuses to take it orally. This inbox behavior occurs to varying degrees among the different species of animals, and essentially depends on their conventional eating habits. Unfortunately, only a few active ingredients have a neutral taste, so that the problem being discussed here is almost always present. In the case of a human patient, an unpleasant tasting active ingredient can be masked relatively easily, e.g. by coating it with a neutral-tasting or sweet layer. Everybody has come across gelatin capsules or tablets coated with sugar or lacquer at some time or other. It is easy to instruct the human patient to take the preparation without chewing. An animal must have a natural willingness .to take a medicinal preparation orally, which mar that the medical preparation must taste well and be palatable. Of course, an individual animal of a few animals can also be forced to take a medicament, by wreaking it swallow or by injecting it. However, such forced methods are not only unacceptable to large animal operations but also to single dogs and cats which tend to bite or scrape if they are not willing to be treated. This is why animal treatment can be very labor-intensive or can require the intervention of a veterinarian and this ultimately leads to increase of costs. Therefore, for pets but equally for animals that are kept on a large scale, simple and safe oral application forms are required, which can be easily administered by the animal keeper, which lead to reliable results, and which are affordable. The chewable composition according to the present invention is not only suitable for replacing the treatment with a tablet or capsule. These chewable can also easily be mixed with conventional non-medicated feed pellets If herds of animals have to be treated. Due to their excellent palatability the chewables according to the present invention are taken up by animals without causing any acceptance problems. Their handling is easy and safe, and can be adapted to the need either of an individual animal like a cat or a dog or to a herd animals like sheep and cows. When reviewing the administration of capsules and coated tablets to animals, it has been shown that these application funs are rather unsuitable for animal medicine, since in the case of herd animals they can only be used in a controlled manner with considerable effort on a daily basis, and in the case of pets, such as dogs and cats, lead to particular acceptance problems. As already mentioned above, the eating habits of animals generally play a decisive role when using oral application forms. Thus, most important is an attractive taste and the palatability. In the case of dogs, it has been observed that they gnaw at solid food, e.g. on bones, and gulp down other food, either in the form of large scraps or wet formulated food, almost unthawed. If a tablet or coated tablet is mixed with the wet formulated feed, varying results are obtained. In a few cases, the tablet is not noticed by the dog at all and is simply gulped down, and in other cases it remains uneaten in the dog bowl. In contrast to dogs, cats are considerably more fastidious in their eating habits. Only in the rarest cases can a tablet or coated tablet be mixed with the formulated food, without them noticing it immediately and rejecting it. Although cats also to not exactly chew their food, they generally break it down with a few small bites. They thereby damage the protective coating of a tablet or capsule and release the unpleasant tasting active ingredient Attempts to mix the active ingredient fireclay with the feed likewise fail, because either the degree of dilution is insufficient to nurture the unpleasant taste or the active ingredient breaks down too rapidly when in contact with the feed. For the same reasons, mixtures of feed, active ingredient and exponents, which should stimulate the appetite of dogs and cats, similarly do not have a successful outcome with cats. Whereas the test animals rush eagerly to a placebo which has a corresponding appetite stimulant, i.e. a tablet consisting of feed, flavoring and other percipients. but no active ingredient, the test animals reject the same combination as soon as active ingredient is added. Cleared, a different technical solution must be found to the existing problem with animals. Of course, any other active ingredient which is suitable for animals can be administered according to the present invention, but especially those active ingredients that have the taste disadvantages mentioned initially and are therefore not willingly taken orally by animals. Basically, a diversity of individual active ingredients or mixtures of active ingredients may be considered, e;g. those-acting-against-exothermal (recto)-or1ntemah(endow)-parasites-erective— ingredients acting against animal diseases including viral or bacterial infections, behavioral disorders, such as hypo- or hyper-activity, inflammatory diseases, and auto-immune diseases. Thus, the active ingredient can be a pesticide or a medicament or a mixture of both. It should be kept In mind that the present invention deals with an optimized application form for veterinary compositions rather than with the treatment of animals with a specific class of active ingredients. On the contrary, the present invention provides an easy-to-use, safe. powerful, and stable veterinary formulation consisting of a highly palatable ductile chewable veterinary composition, which allows to administer orally almost each and any active ire gradient to a warm-blooded animal, provided that this active ingredient or mixture of active ingredients is at the administered dose physiologically acceptable to the animal, does not display unacceptable side effects and, what is most important, exhibits after oral uptake systemic activity. This means that the main prerequisite for the active ingredient is that after oral administration it is taken up by the body fluids, including blood and lymph, and trarisported to the animal pest, the pathogen or the diseased organ where it can exhibit its activity. Thus, any active ingredient or class of active ingredients mentioned hereinafter is nutlike but a non-limiting example of suitable active ingredients. The application form of tine present invention is actually not limited to existing active ingredients but also suitable for each and any active ingredient developed in the future provided that the future active ingredient meets the main characteristics explained hereinbefore. The highly palatable ductile chewable veterinary composition of the present invention is in principle a medicated food product and everybody working in this area is aware of the technical problems that arise in context with the production of medicated feed. For example, stability of the active ingredient is very comical. It is a matter of fact that many potent active compounds are somewhat unstable (temperature-sensitive), above all when in contact with feed material, especially close contact to vegetable and animal materials, during conventional expulsion of feed pellets, result in considerable losses of active ingredient. For example, when feed pellets are prepared via extrusion, the dried organic starting material of animal or vegetable origin is ground, is intimately mixed with the active ingredient, that is to say is substantially homogenized, and then is moistened with water or steam and is -compressedHnto-pellet - ssures-of-aroundH60i bad However, said high pressures and the permanent high temperatures in the range of 60-100 are disadvantageous and do not only dramatically reduce the viscosity of the pellets but result in a considerable lost of active ingredient. Whereas most active ingredients in pure form or in contact with carriers that are routinely used in the production of tablets or capsules withstand such relatively high temperatures per se very well and can be stored in pure form or as tablets or capsules at room temperature for months or years without any measurable loss of active ingredient, they decompose relatively rapidly under pressure and in Intimate contact with animal or vegetable fibers in feedstuff and under the prevailing elevated temperatures. It appears that contact with the fibers actually catalyses the decomposition process. Even when the elevated-pressure and elevated-temperature phase is kept as short as technically possible and the finished pellets are immediately cooled down to room temperature directly after the compression process, a quarter to a third of the active ingredient is nevertheless lost. Even though in the rare cases where the degradation products do not have disadvantageous effects on the animate treated, the unavoidable loss of active ingredient inevitably results in a considerable Crease in the cost of the final product. Thus extrusion processes can lead to very Ltfxiesirable effects. For the reasons mentioned, therefore, much effort has been directed at stablli2ir>g temperature-sensitive active ingredients so that they withstand the elevated temperatures and pressures during pellet preparation without loss of active substance and also, when in the form of the finished pellets, have a long-term storage stability suitable for practical purposes. Unsuccessful attempts at such stabilization Include, for example. (1) reduction of the active ingredient surface area by means of compression into granules, a very great variety of granule sizes having been tried; (2) sealing of the said active ingredient granules in a very great variety of protective layers, for example gelatin or various sugars and coatings; (3) enclosure of the active ingredient within porous materials such as, for example, various celluloses, starches, solicit acids or zealot’s, with or without additional protective layers; and (4) chemical modification of the basic macrocodes structure of the active ingredient Although in a few cases chemical modification has resulted in improved stability of the comporting per serit4ias-stnrtt:ritaneotisiy-resdItedHnHoss-of-activity^ However, none of those attempts has resulted In an appreciably smaller loss of active ingredient on compression into feed pellets or in measurably improved storage stat elite. Moreover, success has now been achieved, surprisingly, in providing the user with the user-friendly, easy-to-use, safe, powerful, stable, and especially highly palatable chewable veterinary composition of the present invention. Astonishingly, it is now possible to provide a product that not only withstands the extrusion process undamaged but also survives for a outstanding long storage period. Therefore, It is highly surprising and was absolutely unpredictable that even so the chewable veterinary composition of the present invention contains a relatively high amount of meat material, this has obviously when combined with the appropriate amount of partially gelatinized starch, no adverse effect on the stability of the active ingredient. It actually turned out that the chewable veterinary composition "of the present invention is a very stable product that can be stored at room temperature over many months without significant loss or degradation of active ingredient. Tests with stored material demonstrate that the palatability is not decreased and the efficacy of the active ingredient stays at a high level. Moreover, investigations of the kinetic behavior demonstrate another surprising effect. It could not have been foreseen that the administration of the chewable veterinary composition of the present Invention could lead to absolutely the same level of bioavailability as the administration of tablets or capsules. Thus, the present invention provides a safe, easy to use and stable product that is at least as efficacious as conventional oral application forms. like tablets or capsules. Many biocides and veterinary medicines that may be now be incorporated Into the chewable veterinary composition and be used according to the present invention, have been known to skilled specialists for a long time but the conventional oral dosage forms are not satisfactory because they are not attractive for animals and show the disadvantages discussed above. With the chewable veterinary composition of the present invention one can combat all kinds 1^fpafasites7-Exte 1a paras!tes7also- lied-echo-parasites are-understood which normally live on the animal, i.e. an the animal's skin or in the fur. Enclosed are biting insects, such as mosquitoes, blowfly, fleas or lice, or members of the order Acam7a, e.g. mites or ticks. Suitable products against extremely parasites include insecticides and acaroids. It does not matter what their mode of action actually is. They can be e.g. chitin synthesis inhibitors, growth regulators; juvenile phonons; adulteries. They can be broadband insecticides, broadband acaroids. The active ingredient can be a killer or a deterrent or repellent It can affect e.g. only adult stages or juvenile stages of the parasite or may affect any stage. The only prerequisite is that the active ingredient acts systemically. This means that it is not decomposed after oral uptake but transported by the body fluids to the skin or organ where the parasite uses to live. If the active ingredient is an scarified one can, for example, select a systemically acting acaroids from one of the following well-known daces of acaroids intruder g: antiskid acaroids such as abamectin, doramectin, eprinomectin, ivermectin, milbemectin, nikkomycins. selamectin. tetranactin, and thuringiensin; bridged biphenyl acrider such as azobenzene, benzoximate, benzyl benzoate, brbmopropylate, clot snider, chlorfenethd, chlorfenson, chlorfensulphide, chlorobenzilate, chloropropylate, icefall. biphenyl saffron, dofenapyn, fanon, fentrifanil, fiuorbenside, protocol, titration, and tetras; catamite acaroid’s such as binomial, carbanolate, carbaryl, cartxjfuran, fenothiocarb. methkx:arb, metacarpi , primacy, and pronoun; oxides carbonate acaroid’s such as aldicarb. butocarboxim. oxamyl. thiocarboxime, and thiofanox; dinltrophenol carbides such as binapacryl, dinned, diminution, din cap, dinocap-4, dinocap-6, demotion, dinopenton, dinosulfon. dinoterbon, and DNOC; formamidine accuracies such as amrita. chlordimefomi, chloromebuform. formetanate, and formparanate, mite growth regulators such as clofentezine, dofenapyn, fluazuron, flubenzimine, flucycloxuron, flufenoxuron, and hexythiazox; organ chlorine acaroids such as bromocyclen, camphechlor, dienochlor. and endosulfan; organizing accuracies such as azocydotin, cheatings, and fenbutatin oxide; paranoid accuracies such as acetoprole, Prone and analogues and derivatives thereof, tebufenpyrad, and vaniliprole; parathyroid acaroids Induding: pyrethroid ester acariddes Bee acrinathrin, bifenthrin, cyhalothrin, cypermethrin, alpha-cypermethrin, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvaJinate, tau-fluvalinate, and permethrin, and pyrethroid ether acaroid’s like hatfenprox; quinoxaline acaroid’s such as chinomethionat and thioqulnox; sulfite ester acaroid’s such as propagated; tectonics acid acariddes such as spirodidofenrand-from-unclassified-acariddes-such acequ'mocylramidoflumetrarsenoas-oxide, chloromethiuron, decanted, crotamlton, diafenthiuron, dichlofluanid, disaffirms, fenazaflor, fenazaquin, fenpyroximate, fluacrypyrim, fluenetil. maculae, MNAF, nifluridide. pyridines, pyrimidifen, sulfiram, sulfluramid, sulfur and triarathene. Suitable insecticides acting either as adulteries or inset growth regulators (Girls) can be chosen from a variety of well-known different chemical dashes such as chlorinated hydrocariDons, organophosphates, car amates. parathyroid, formalities, borates, phenylpyrazoles, and macrocodes lardoons (previously known as avermectins . Prominent representatives of adulteries/insect killers are imidacloprid, mention, fibroin, allethrin, resection, fenvalerate, perverting, halation and derivatives thereof. Insect autacoids kill the insect in almost any development stage either by contact or as a stomach poison. Widely used representatives of insect growth regulators (Ergs) are, for example benzoytphenylureas such as diflubenzuron, lufenuron, novifiumuron. hexaflumuron, triflumuron, and teflubenzuron or substances like fenoxycarb, pyriproxifen, methoprene, isoprene, hydro Rene, chromatin, buprofezin, pymetrozine and derivatives thereof. Insect growth inhibitors or insect growth regulators (any” of which is commonly known as an IGR) are products or materials that interrupt or inhibit the life cycle of a pest. It goes without saying that the highly palatable ductile chewable veterinary composition accountings to the present invention is also very suitable for administering active ingredients that combat internal parasites (ends-parasites) such as worms living in the blood or in organs of the animal. Thus, the active ingredient can be an anathematic (deformer). Anthelmintics (deformers) are a heterogeneous group of drugs but they are selectively toxic to worms. The drugs can achieve this by either inhibiting the metabolic process vital to the parasite, or by causing the parasite to be exposed to higher concentration of drug than are the hosts cells, which means that one makes use of the existence of an advantageous therapeutic window. Anthelmintics can affect the target parasite during treatment by interfering with the integrity of parasite cells, inhibiting neuromuscular transmission and coorcfination, or mechanisms which protect against host immunity, that ultimately lead to the starvation, neuromuscular paralysis, death and expulsion of the parasite. Anthelmintics are commonly administered by drench, paste, orally, or by injection. The drugs are absorbed into the broody stream and widely diffused. They are metabolized in the liver and excreted in feces -and-orange n he-animal-health^feld-antf1elmintics-are-used-widely-iJsed-^gainst-foun^ lungworms, tapeworms, intestinal worms, whipworms, hookworms, pinworms, trichinella (trichinosis), and other less common organisms, liver flukes and other less common organisms in a broad range of animals such as beef, cattle, swine, goats, horses, and pets like cats and dogs. The activity spectrum of anthelmintics for dogs and cats embraces Treatises such as Alicia balata and Opisthorchis tenuicollis] Cestuses such as Tania hydatigena, Tanya pisifonvis, Tanya obis, Hydatigena Tania taeniaeformis, Ecfiinococcus granulizes, Echinococcus multilocularis, Dipylidium cranium, Diphyliobotlirium alum, Multicast malice’s, Malice’s serial’s, Mesocestoides lineate, and Mesocestoides cortex; and Nematodes such as Ancylostoma cranium, Unitarians stenocephaia, Oxcart canes, Boxcar cacti] Toxascaris leonine, Strongyloides stercoralis, Fluorides osier] Capybara necrophilia, Capillaries pica, Capillaria hepatica, Trichinella spiral’s, Angiostrongylus vacuum, Brochures gulps, Spirocerca lumpy, Dirofilaria imides, Ancylostoma tubaeforme, and Aelurostrongyius abstrusus. Internal parasites within the present invention include all species of worm infestation (helminthes) but also bacteria’ and viruses causing bacterialahd viral infections, in patrician those that infest the organs or parts of the body, such as the lungs, heart, carpentry tract or extremities, or which spread through the whole organism. The anathematic can be selected from endo-parasiticides and undecided including one of the following well-known groups of deformers such as macrocycfic lactones (sometimes called simply macro ides), benzimldazoles, pro-benzimldazoles, imidazothiazoles. tetrahydropyrimidines, organophosphates and piperazines. A most preferred group of anthelmintics consists of the more modem natural or chemically modified macro cyclic lactones (macro ides), such as avermectins, milbemycins and derivatives thereof, Including prominent representatives such as Ivermectin, Doramectin. Moxidectin, Selamectin, Emamectin, Eprinomectin. Milbemectin, Abamectin, Milbemydn oxide, Nonaddicting. and a derivative thereof, in free form or in the form of a physiologically acceptable salt. The macro cyclic lactones are most preferred because they exhibit a broad spectrum of activity. Most of them exhibit recto and in parallel endo-parsiticidal activity. Therefore, they caHed"endectoddesrMaa'ocyclic4actones4Dind o-agglutinated-chlorine causing in the first instance paralysis and later on the death of the parasite. In the context of the invention, a preferred group of macrocyclic lactones is represented by compounds of formula (I) wherein X is -C(H)(OH)-; -C(0)-; or -C(=N-OH)-; Y is -C(H2)-; =C(H)- ; -C(H)(OH)"; or -C(=hf-OCH3)-; Ri is androgen or one of radicals R4 is hydroxyl. -NH-CH3 or -NH-OCH3; R2 is hydrogen. -CH3, -C2H5. -CH(CH3)-CH3, -CH(CH3)-C2H5. -C(CH3)=CH-CH(CH3)2 or cyclohexyl; and if the bond between atoms 22 and 23 represents a double bond the carbon atom in 23-posltion is unsubstantiated so that Y is =C{H}-, or if is the bond between atoms 22 and 23 is a single bond the carbon atom in 23-position is unsubstantiated or substituted by hydroxy or by the group =N-0-CH3 so that Y is -C(H2)-; -C(H)(OH)- ; or -CC-N-Lochs)-; in free form or in the form of a physiologically acceptable salt. Typical and especially preferred representatives of compounds of formula (I) are: 1) Ivemiectin is 22,23-Dihydroabamectin; 22,23-dihydroavermectin B 1; or 22,23-dihydro C-076B 1, wherein X is -C(H)(OH)-; Y is -C{H2)-; Ri is the radical R2 is either -CH(CH3)-CH3 or -CHCCHshCaHs and the bond between atoms 22 and 23 represents a single bond, ivennectin is known from US-4.199.569. 2) Doramectin Is 25-Cyclohexyl-5- O- demethyl-25-de(1-methylpropyl)averment Ala, wherein X is -C(H)(OH)- ; Y is =C(H}-; R1is the radical R2 is cyclohexyl and the bond between atoms 22 and 23 represents a double bond. Doramectin is known from US-5,089,480, 3) Moxidectin, is [6 R ,23 E, 25 S ( E )]-5- O- Demethyl-28-deoxy-25-(1.3^imethyl-1. botany)-6,28-epoxy-23-(ethoxy imp into)milbemycin B, wherein X is -C(H)(OH)-; Y is - C(=N-OCH3r; Rib IS hydrogen; R2 is -C(CH3)=CH-CH(CH3)2; and the bond between atoms 22 and 23 represents a single bond. Moxidectin, is known from EP-0,237,339 and US- 4,916,154, 4) Selamectin is 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22,23-dihydro-5- (hydroxyimino)avenmectin B1 monosaccharide and thus a compound of formula (i), wherein X is_-C(=N-OH)-; Y is -_C(H2)S R1 is the radical R2 is cyclohexyl; and the bond between atoms 22 and 23 represents a single bond. Selamectin is known e.g. from: ECTOPARASITE ACTIVITY OF SELAMECTIN; A novel insecticides for dogs and cats. A Pfizer Symposium, held in conjunction with The 17th international Conference of the World Association for the Advancement of Veterinary Parasitology, 19 August 1999. Copenhagen, Denmark. 5) Emamectin is (4primeprime R )-5- O -demethyl-4primeprimedeoxy-4primeprime- (methylamine) averment A la and (4primeprime R )-5" O -demethyl-25-de(1-methylpropyl)- 4primeprime-deoxy-4primeprime-(methylamine)-25-(1"methylethyl)avermectinAla (9:1). wherein X is -C(H)(OH)-; Y is =C(H)-; R1 is - R2 is -CH(CH3)"CH3, or -CH(CH3)-C2H5, and the bond between atoms 22 and 23 represents a double bond. Emamectin is known from US-4,874,749. 6) Eprinomectin is (4primeprime R )-4primeprime- (acetylamlno)-4primeprime- deoxyavemiectin B 1, wherein X is -C(H)(OH)-; Y is =C(H)- ; R1 is the radical R2 is -CH{CH3) X is -C{H)(OH}- ; Y is -C(H2)-; R is hydrogen; R2 is -CH3, or -C2H5; and the bond between atoms 22 and 23 represents a single bond. Milbemectin is known from US-3,950,360. 8) Abamectin is Avermectin B 1 which is also named 5- O- demethylavermectin A 1a and 5-O- demethyl-25-de(1"methylpropyi)-25-(1-methylethyI)avermectin A 1a (4:1), wherein X is -C(H)(OH)-; Y is =C(H)-; Ri is the radical R2 is -Cachucha. or -CH(CH3)-C2H5; and the bond between atoms 22 and 23 represents a double bond. Abamectin is known from US,310.519. 9) Milbemycin axiom is milbemycin A 4 5-oxime; milbemydn A 3 5-oxime. wherein X rasp - C(H)(OH)- ;; Y is -C(H2)-; Rip is hydrogen; Mrs. is -CH(CH3)-CH3. or-CHCCHsCzHs, and the bond between atoms 22 and 23 represents a single bond. Milbemycin oxlip is known from US-4,547,520. 10) The compound of the formula (I) wherein X is -C{H)(OH)- ; Y is -C{H^] R^ is the radical Ra is -CHs or C2H5, and the bond between atoms 22 and 23 represents a single bond. This compound is known from WO 01/83500. 11) Nonaddicting is antibiotic S-541A; also named [6 R. 23 S, 25 S.(E) ]-5- O Dimity[-28- deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-hydroxymilbemycin B; wherein X is =CH- OH; Y is -C(H2)-; R is hydrogen; R2 is -C(CH3)=CH-CH(CH3)2, and the bond between atoms 22 and 23 represents a single bond, Nonaddicting is known from US-4.869,901. I compounds specmcaiiy mentioned ulnae items i-n nereinoerore, are preened embodiments of the present invention and can be used either alone or in combination with another endo-parasiticide, ecto-parasiticide or insecticide. Benzimidazoles, benzimidazole carbonated and pro-benzimidazoles interfere with energy metabolism by inhibition of polymerization of microtubules and include very potent compounds such as thiabendazole, mebendazole, fenbendazole, oxfendazole, oxibendazole. albendazole, luxabendazole, netobimin, parbendazole, flubendazole, cyclobendazole, feasted, hyphenate and derivatives thereof. Imidazothiazoles are cholinergic agonists and include highly active compounds such as tetramisole, levamisole. and derivatives thereof. Tetrahydropyrimidines act are also cholinergic agonists and Include highly active compounds such as ornately, parental, and derivatives thereof. Organophosphates are inhibitors of cholinesterase. This class includes potent compounds such as dichlorvos, halloo, trichlorfon, and derivatives thereof. Piper zanies exhibit anticholinergic action and block neuromuscular transmission. This class indudestiighly active compounds such as pauperizing and derivatives thereof. S cyanides selected from collate, tribromsalan, dibromsalan, oxychlozanide, dioxanide, rafoxanide, botanies. bromoxanide and derivatives thereof. Within the present invention the anathematic (deformer) a preferred embodiment consist of a combination of a macrocyclic lactones and an anathematic selected from the group consisting of Albendazole, Corpulent, Cadetting, Diethylcarbamazine, Debate, Fenbendazole, Haledon, Levamisole. Mebendazole, Ornately, Oxyclozanide, Oxibendazole, Oxfendazole. Oxfendazole, Oxamniquine, Pirates, Piperazine, Praziquantel, Thiabendazole. Tetramisole, Trichlorfon, Thiabendazole, and derivatives thereof. Most preferred is Praziquantel, In order to broaden the activity spectrum towards cot-parasites said anathematic combination can contain in addition to the deformers a parasitic dally effective amount of an insecticide, acetified or an insedicide and an accuracies. Of course one could also add an antibiotic for treating bedevil disease. All of the suitable parasitic ides mentioned hereinbefore are known. Most of them are described in THE MERCK INDEX 1999 by Merck & Co Inc, Whitehouse Station, NJ, USA; pub shed on CD-ROM by Chapman & Hill/CRC, 1999. Hampden Data Service Ltd. and in Julie nteratuceLspecificallyjpentionedJpJnJEJERCIC Suitable ant microbial active ingredients are, e.g. various penicillin’s, tetracycline’s, sulfonamkles, cephalosporins, cephamycins, aminoglucosids, trimethoprim, dimetridazoles, erythromycin, gramicidin, fruazolidone, various pleuromutilins such as timeline, valnemulin, various macro ides, sti'eptomycin and substances acting against protozoa, e.g. clop idol, saiinomycin, modernism, haiofuginone, harassing, rebinding, etc. Behavioral disorders include e.g. separation worry or travel sickness of dogs and cats. A suitable compound acting against behavioral disorders is e.g. clomipramine. The chewable combination according to the present invention may also contain an active ingredient for the treatment of disfunctions or hypo-activity, Dysfunction or hypo-activity is understood to include functions like autoimmune disorders, which deviate from the norm; whether through inborn or acquired damage to organs or tissue. This complex also includes rheumatic diseases, pathological chastises to joints, bones or internal organs, and much more. A prominent representative of compounds that can be used in this complex area is cyclosporine and derivatives thereof. The term "animal disease" even includes different types of cancer and metastasis progression in connective tissues that are common in animals. In this field bisphosphonates like coledronate, coordinate, etidronate, pomegranate and alendronate play an important role. Said bisphosphonates can also be administered in the treatment or prophylaxis of ulcers, rheumatoid arthritis and other actinides, and periodontitis. Knottier suitable ads of active ingredients encompasses anti-Inflammatory agents such as benzene sulfonamides like Draconic, which is extremely suitable for the control of pain and inflammation associated with osteoarthritis. Further anti-inflammatory agents are diclofenac and derivatives thereof. In the present invention, the administration problems depicted in connection with conventional oral dosage forms, like tablets and capsules, can be very easily resolved and chewable products can be prepared, which are taken orally by the animals without causing any problems. The animals actually take the chewable veterinary compositions voluntary. -Summarv-of-the-lnvention- The present invention overcomes the disadvantages and shortcomings of the prior art by providing an easy-to-use, safe, powerful, and stable veterinary formulation consisting of a highly palatable ductile chewable veterinary composition which is produced by an extrusions process wherein the product is extruded at or near room temperature, and where the extruder is cooled down below room temperature, preferably to 5-10°C. The palatable ductile chewable composition constitutes a veterinary composition and is administered orally. The composition is capable of killing endue-parasites and extol-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any want-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. The highly palatable ductile clearable veterinary composition of the invention is composed of an organic composition which contains an effective amount of one or more active gradients, preferably an effective amount of a mono, binary or tamari mixture of organic compounds ‘capable of controlling cot-parasites, endue-parasites or bacterial’ or verbal pathogens or a combination of ecto-parasrtes. endue-parasites. bacterial or viral pathogens. Dejecting on the mode of action the highly palatable ductile cheval able veterinary composition of the invention contains a parasitic dally or anti-pathogenically effective amount of one or more active ingredients. The expression "parasitic dally effective amount" refers to that amount of active ingredient in the composition ich will fully control the target parasite which means that 95-100%, preferably 98-100% or close to 100% of the parasites are killed and the active ingredient is nevertheless well tolerated. The expression "anti-pathogenically effective amount" refers to that amount of active ingredient in the composition which will efficiently cure a bacterial, viral or behavioral disease or if administered prophylactic ally will suppress the outbreak of such a disease. The highly palatable ductile chewable veterinary composition of the invention comprises an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; it further comprises meat flavoring and partially gelatinized starch, and It comprises of a softener; and of up to 9 % (w/w), preferably 3-7 % (w/w), most preferred 4-6 % (w/w), of water. It is essential that that during the extrusion process the extruder is cooled down below room temperature. A temperature range of 5-10**C is ideal. Each-of the folle ring-par-agraphs-defines-a-pFeferred emb9diment-of#ie-pFeseRt-inventienf A highly palatable ductile chewable veterinary composition that comprises (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) optionally up to 9 % (w/w) water, A highly palatable ductile chewable veterinary composition as defined above capable of controlling endow-parasites and simultaneously recto-parasites of non-human animals. A highly palatable ductile chewable veterinary composition as defined above wherein the animal disease comprises bacterial infections, viral infections, behavioral disorders, inflammatory diseases, and auto-immune diseases. A highly palatable ductile chewable veterinary composition as defined above comprising 20 to 30 % (w/w) of a natural meat flavoring. A highly palatable ductile chewable veterinary composition" as defined above wherein the natural meat flavoring comprises 20 to 55 % (wavy) fat. A highly palatable ductile chewable veterinary composition as defined above comprising 25 to 70 % (w/w) of partially gelatinized starch. A highly palatable ductile chewable veterinary composition as defined above wherein the partially gelatinized starch comprises 12 to 17 % (w/w) of gelatinized starch. A highly palatable ductile chewable veterinary composition as defined above comprising 10 to 20 % (w/w), preferably about 11-15 % (w/w). of a softener, based upon the weight of the partially gelatinized starch. A highly palatable ductile chewable veterinary composition as defined above wherein the softener is selected from the group consisting of glycerol, polyethylene glycol and polypropylene glycol. A highly palatable ductile chewable veterinary composition as defined above comprising up tQ-9-%-(wAA4i- A highly palatable ductile chewable veterinary composition as defined above comprising 1 to 10 % (w/w), preferably 3 to 7 % (w/w) of a sweetener. A highly palatable ductile chewable veterinary composition as defined above comprising 0 to 3.5 % (w/w), preferably 0.01 to 0.5 % (w/w) of an antioxidant. A highly palatable ductile chewable veterinary composition as defined above comprising 0 to 5 % (w/w), preferably 0.05 to 2 % (w/w) of a coloring agent. A highly palatable ductile chewable veterinary composition as defined above comprising 0 to 4% (w/w) of sodium chloride. A highly palatable ductile chewable veterinary composition as defined above comprising an parasftiddally effective amount of an ecto-parasiticide, an endo-parasiticide, an insecticides or of a combination of a parasitoid selected from the group consisting of an ecto-parasiticide, an endo-parasiticide and an insecticides. A highly palatable ductile chewable veterinary composition as defined above wherein the ecto-parasiticide is active against insects, members of the order Ocarina or insects and met)errs of the order Ocarina. A highly palatable ductile chewable veterinary composition as defined above wherein the ecto-parasiticide is an insecticide which is either an insect adulteries or insect growth regulators. A highly palatable ductile chewable veterinary composition as defined above comprising an parasitiddally effective amount of an endo-parasiticide or insecticide selected from the group consisting of macrocyclic lactones, benzimidazoles. pro-benzimidazoles , imidazothiazoles, tetrahydropyrimidines, organophosphates and piperazines. A highly palatable ductile chewable veterinary composition as defined above comprising an -egectwe- R4 is hydroxyl, -NH-Chan or-NH-Ochoa; R2 is hydrogen, -CH3. -C2H5. -CH(CH3)-CH3. - CH(CH3)-C2H5. -C(CH3)=CH-CH(CH3)2 or cyclohexyl; and if the bond between atoms 22 and 23 represents a double bond the carbon atom in 23-position is unsubstantiated so that Y is =C(H)-, or if is the bond wine atoms 22 and 23 is a single bond the chart)n atom in 23- position is unsubstantiated or substituted by hydroxy or by the group =N-0-CH3 so tibia Y Is - C(H2)-; -C(H)(OH)-; or -C(=N-OCH3)s in free frond or in the foamy of a physiologic acceptable salt.. A highly palatable ductile chewable veterinary composition as defined above comprising an effective amount of a natural or chemically modified macrocyclic lactones of formula (I) wherein X is -C(H)(OH)- ; Y is -Cache)-; Ri is the radical R2 is -CH3 or C2H5, and the bond between atoms 22 and 23 represents a single bond. A haggy palatable ductile chewable veterinary composition as defined above wherein \he animal pests are external animal parasites or internal animal parasites or both. A highly palatable ductile chewable veterinary composition as defined above wherein the macrocode lactones is selected from the group consisting of avermectins, milbemycins and derivkives thereof, in free form or in the form of a physiologically acceptable salt. A highway palatable ductile chewable veterinary composition as defined above wherein the macrocydic lactone is selected from the group consisting of Ivermectin, Doramectin, Moxidectin. Selamectin, Emamectin, Eprinomedin, Milbemedin, Abamectin, Milbemycin oxeye, Nematode, and a derivative thereof, in free form or in the form of a physiologically acceptable salt. A highly palatable ductile chewable veterinary composition as defined above comprising an effective amount of a macrocydic lad one in combination with an effective amount of an anathematic seeded from the group consisting of Albendazole, Corpulent, Codeine, Dietiiylcarbamazine, Debate, Fenbendazole, Haledon, Levamisole, Mebendazole, Morantel, Oxyclozanide, Oxibendazole, Oxfendazole, Oxfendazole, Oxamniquine, Pyrantel, Piperazine, Praziquantel, Thiabendazole, Tetramisole, Trichlorfon, Thiabendazole, and a derivative thereof A highly palatable ductile chewable veterinary composition as defined above comprising additionally an effusive amount of an insedicide, acaroids or an insecticide and an —wearied A highly palatable ductile chewable veterinary composition as defined above comprising an effusive amount of milbemycin oxide and praziquantel. A highly palatable ductile chewable veterinary composition as defined above comprising an effusive amount of lufenuron, praziquantel and milbemycin oxide. A highly palatable ductile chewable veterinary composition as defined above comprising an effective amount of cyclosporin. A highly palatable ductile chewable veterinary composition as defined above comparing an effective amount of an antimicrobial selected from the group consisting of a penile, tetracycline, sulfonamide, cephalosporin, cephamydn, aminoghjcosid. trimethoprini, dimetridazole, erythromycin, gramicidin, fruazolidone, pleuromutirin, streptomycin ark a compound that is active against protozoa. A highly palatable ductile chewable veterinary composition as defined above comprising an effective amount of compound that is active against behavioral including separation worry or travel sickness of dogs and cats. A highly palatable ductile chewable veterinary composition as defined above wherein the active ingredient or a different chemical class is an insecticide or acaroids. A highly palatable ductile chewable veterinary composition as defined above wherein th insecticide is selected from the group consisting of insect killers and insect grower regulators. Another preferred embodiment of the present invention is a method of controlling said animal pests or pathogens and of curing or preventing said animal diseases by feeding an animal with said highly palatable ductile chewable veterinary composition. Yet another preferred embodiment of the present invention is a method of contend ling said -animal-pests-eFpathegens-and-of-ouring-er-preventing-said-animal- -an animal with said highly palatable ductile chewable veterinary composition. Yet another preferred embodiment of the present invention is a process for the production of a highly palatable ductile chewable veterinary composition as defined above, comprising 0) feeding the hopper of an extruder with an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; meat flavoring; partially gelatinized starch; a softener; and up to 9% (w/w) of water, (ii) cooling constantly down the mixture of active ingredients and carriers so that the temperature of the extrudate in the extruder does during the whole extension process at no time exceed 40°C, (iii) pressing the extnjdate through a die that is decisive for the shape of the chewable product, and (iv) cutting the excaudate that leaves the ectoderm into equal pieces. Yet another preferred embodiment of the present invention is a process as defined above wherein the hopper of the extender is fed continuously and simultaneously with pre-mixture (1) and pre mixture (2), wherein pre-mixture (1) consist of a homogenized mixture of one or more active ingredients and partially gelatinized starch, and pre-mixture (2) consists of a homogenized mobsters of meat flavoring, a softener and optionally of a carrier selected from the group consisting of a sweetener, softener, an antioxidant, a coloring agent and sodium chloride. Yet another preferred embodiment of the present invention is a process as defined above wherein the extruder is cooled down below room temperature. A further profaned embodiment of the present invention is a method of controlling nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases comprising feeding an animal with a palatable ductile chewable veterinary composition as defined above. A further preferred embodiment of the present invention is a method as defined above, wherein the palatable ductile chewable veterinary composition consist of one chewable portion containing an effective amount of a compound or mixture of compounds capable of controlling nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases. A further preferred embodiment of the present invention is a method as defined above, wherein the amount of active ingredient is adjusted to the bodyweight of the nonhuman animal that is in need of the treatment. Another preferred embodiment of the present invention is the use of (A) an effective amount of one or more Ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; (E) up to 9% water, and an active ingredient suitable for combating animal pests, pathogens or animal diseases for the preparation of a highly palatable ductile chewable veterinary composition. Another preferred embodiment of the present invention is the use as defined above, comprising 20 to 30 % (w/w) of a natural meat flavoring. Another preferred embodiment of the present invention is the use as defined awe. where the natural meat flavoring comprises 20 to 55 % (w/w) fat.' Another preferred embodiment of the present invention is the use as defined ale comprising 25 to 70 % (w/w) of partially gelatinized starch. Another preferred embodiment of the present invention is the use as defined above, wherein the partially gelatinized starch comprises 12 to 17 % (w/w) of gelatinized starch. Another preferred embodiment of the present invention is the use as defined above, comprising 10 to 20 % (w/w) of a softener, based upon the weight of the partially gelatinized starch. Another preferred embodiment of the present invention is the use as defined above, wherein the softener is selected from the group consisting of glycerol, polyethylene glycol and polypropylene glycol. Another preferred embodiment of the present invention is the use as defir)ed above, comprising 3 to 7 % (w/w) of water. Another preferred embodiment of the present invention is the use as defined above, wherein the animal pests are external animal parasites or internal animal parasites or both. Another preferred embodiment of the present invention is the use as defined above, comprising 1 to 10 % (w/w) of a sweetener. Another preferred embodiment of the present invention is the use as defined above, comprising 0 to 3.5 % (w/w) of an antioxidant Another preferred embodiment of the present invention is the use as defined above, comprising 0 to 5 % (w/w) of a coloring agent. Another preferred embodiment of the present invention is the use as defined above, comprising 0 to 4% (w/w) of sodium chloride. Unifier preferred embodiment of the present invention is the use as defined atone, comprising an parasitic dally effective amount of an ecto-parasiticide, an endo-parasiticide, an insecticide or of a combination of a parasitic selected from the group consisting of an ecto-parasiticide, an endo-parasiticide and an insecticide. Another preferred embodiment of the present invention is the use as defined above, wherein the ecto-parasiticide is active against insects, members of the order Carina or Insects and members of the order Ocarina. Another preferred embodiment of the present invention is the use as defined above, wherein the ecto-parasiticide is an insecticide which is either an insect adulteries or insect growth regulators. Another preened embodiment of the present invention is the use as defined above, comprising an parasitic dally effective amount of an endo-parasiticide or insecticide selected from the group consisting of macrocyclic lactones, benzimidazoles, pro-benzimidazoles , rnkiazothiazoles, tetrahydropyrimidines. organophosphates and piperazines. AnoSieF^FefeFFed-embodimentof4he-present-iHvention-is4he4Jse-as-defined- comprising an effective amount of a natural or chemically modified macrocyclic lactone of formula (I) R4 is hydroxyl. -NH-CH3 or-NH-OCH3; R2 is hydrogen, -CH3, -C2H5, -CH(CH3)-CH3, -CH(CH3)-C2H5. -C(CH3)=CH-CH(CH3)2 or cyclohexyl; and if the bond between atoms 22 and 23 represents a double bond the carbon atom in 23-position is unsubstantiated so that Y is =C(H)-, or if is the bond between atoms 22 and 23 is a single bond the carbon atom in 23-position is unsubstantiated or substituted by hydroxy or by the group =h4-OCH3 so fiat Y fee -C(H2)-; -C(H)(OH)-; or "C(=N-0CH3)-; in free foment or in the form of a physiologically Another preferred embodiment of the present invention is the use as defined above, wherein the macroscopic lactone is a compound of the formula (I) wherein X is -C(H)(OH)-; Y is -Char)-; R1is the radical Raja is -Oyez or C2H5, and the bond between atoms 22 and 23 represents a single bond. Another preferred embodiment of the present invention is the use as defined above, wherein the erKfectidde is a macrocyclic lactone is selected from the group consisting of avermectirts, milbemycins and derivatives thereof, in free form or in the form of a physiologically acceptable salt. Another preferred embodiment of thepresenf invention is the use as defined above, wherein the macrocydic lactone is selected from the group consisting of Ivermectin, Doramectin, MoxkJectin, Selamectin, Emamectin. Eprinomectin, Milbemectin, Abamectin, Milbemycin chimed, Nemadectin. and a derivative thereof, in free form or in the form of a physiologically acceptable salt. Another preferred embodiment of the present invention is the use as defined above, comprising an effective amount of a macrocyclic lactone in combination with an effective amount of an anathematic selected from the group consisting of Albendazole, Corpulent. Cadetting, Diethylcarbamazine, Febantel, Fenbendazole, Halo on, Levamisole, Mebendazole, Morantel, Oxyclozanide, Oxibendazole, Oxfendazole, Oxfendazole, Oxamniquine. Pyrantel, Piperazine, Praziquantel, Thiabendazole, Tetramisole, Trichlorfon, TWabendazole, and a derivative thereof. Another preferred embodiment of the present invention is the use as defined above, comprises in addition to an endo-parasiticide or an insecticide an effective amount of an undecided, accuracies or an insecticide and an accuracies. Another preferred embodiment of the present-invention inside use as defined above, comprising an effective amount of milbemycin oxides and praziquantel. Another preferred embodiment of the present invention is the use as defined above, comprising an effective amount of lufenuron, praziquantel and milbemycin oxide. Another preferred embodiment of the present invention is the use as defined above, comprising an effective amount of cyclosporin. Another preferred embodiment of the present invention is the use as defined above, comprising an effective amount of an antimicrobial selected from the group consistory of a penicillin, tetracycline, sulfonamide, cephalosporin, cephamycln, aminoglucosid, trimethoprim, dimetridazole, erythromycin, gramicidin, ft-uazolidone, pleuromutilin. streptomycin and a compound that is active against protozoa. Another preferred embodiment of the present invention is the use as defined above, comprising an effective amount of compound that is active against behavioral including separation worry or travel sickness of dogs and cats. An additional preferred embodiment of the present invention is the use of a highly palatal e ductile chewable veterinary composition as defined above in a process of contemning nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases. Detailed Description of the Invention Even so meat flavoring is actually not the main component of the highly palatable ductile chewable veterinary composition it plays the major role for the present invention. It has surprisingly been recognized that the desired high palatability taint is necessary for achieving reliable and well-reproducible results stricter depends on the amount of meat flavoring in Ice final composition. The meat flavoring is either a natural product consisting of dried powdered meat derived, for example, from domestic animals and productive livestock, e.g. pigs, horses, cattle, sheep, goats and poultry including chicken, duck, goose and turkey. It further surprisingly turned out that the natural content of fat in said natural meat powder of 20-55% - for the animal but also for achieving the desired softness of the final chewable product In context v^ the present invention, a "meat flavoring" shall refer to natural dried and powdered meat as well as to artificial meat flavorings, which are well-known from the food industry. It has however be recognized that artificial meat flavorings are only suitable for the present invention if they already contain 2055% (w/w) fat or if this amount of fat is added to the artificial flavoring. Fat that can be added to artificial meat flavorings can be chosen either from animal fats or preferably from plant fats including vegetable oils. However, if vegetable oils are used it is advantageous to use hardened/saturated oils. Unsaturated oils are usually Liquid at room temperature and result in products that do not show the desired ductility/softness. They are usually too soft. Presented is the use of saturated/hardened oils/fats that are generally solid at room temperature and lead to chewable compositions showing the desired ductility. Fats and oils contain many different fatty acids which affect the body in varying ways. Most simply, they are classified as saturated or unsaturated. Saturated fats sometimes are also cubed hardened fats. It is the saturated fat found in many animal products. Saturated fats are g reedy solid at room’ temperature. They are mainly of anural origin but can also be isolated from plants. Typical examples stemming from plants are cocoa butter and coconut and pear oils. These products are often used in store-bought baked goods, non-dairy whipped toppings, cream substitutes, most peanut butter and some margarines. Typical sources of saturated fat are: Animal Fat; Coconut Oil; Meat Fat; Bacon Fat; Cream; Palm Kernel Oil; Beef Fat; Palm Oil; Butter; Ham Fat; Pork Fat; Chicken Fat and Skin; Hardened Fat or Oil; Turkey Fat and Skin; Hydrogenated Vegetable Oil; Cocoa Butter, Lamb Fat; and Coconut Natural and artificial meat flavoring is commercially obtainable from various producers. Natural meat flavoring is. for example, obtainable from: IDF (International Dehydrated Food) INTERNATIONAL DEHYDRATED FOODS. INC. P.O. Box 10347 Springfield, Missouri 65808, USA 800/641-6509 or 417/881-7820 ADF (American Dehydrated Food), American Dehydrated Foods. Inc., P.O. Box4087 3801 East Sunshine. Springfield, Missouri 65809 IFF (International Flavors and Fragrance), IFF Global Headquarters, 521 West 57th Street, New Yogic, NY 10019, United States Profit, Prurient Inc. - U.S. Office. 2325 North Loop Drive Ames. law 50010 USA -Someoxamptes-efsour-ees artifieial-fneat-flavoring Cumin, Worldwide Headquarters • 2100 Mabry Street, Box 70 • Des Moines, Iowa 50301-0070 USA, McCormick, 226 Schilling Circle HuntValley,MD 21031 Givaudan, Givaudan Flavors Corp. (Rivers creation, sales & production) 1199 Edison Drive Cincinnati. Ohio 45216 Headman und Reimer Within the present invention the expression "soft" is used to characterize a product that is not as hard and crunchy as, for example, a cornflake and on the other hand is not as ductile as. for example, a marshmadow. The desired ductility/hardness lies sommeliers in between. If measured with a commercially available TEXTURE ANALYSER that is commodity available from Stable Micro Systems(TA-XT2 iHR/25), the texture (softness/hardies) of the chewables lies ideally between 6 -12 N. Hard and crunchy "products are speedily disadvarltageous if one intends to treat ocher dogs and cats because most of these old animals suffer from periodontal disease (Porte). This disease involves the inflammation and degeneration of tissues that surround and support the teeth. These include the gingival, alveolar bone, periodontal ligament, and cementer. Periodontitis or the loss of supporting bone is the latest stage of this progressive disorder and is the major cause of tooth loss in old dogs and cats. Animals suffering from periodontitis avoid eating hard and crunchy products because they cause them pain. The second important feature of the present Invention is the use or partially gelatinized starch. This starch contains 10-20% (w/w), preferably about 13-17% (w/w), most preferably 13-17% (w/w) pre-gelatinized starch. Thus is important as non-gelatinized and completely pre-gelatinized starch do not result in the desired ductility of the final product Starches exhibit thermal stability to about 121 °C. Starches are carbohydrates of a general formula (C6Hio05)n and are derived from com, wheat, oats, rice, potatoes, yucca and sim8ar plants and vegetables. They consist of about 27% linear polymer (amylase) and about 73% branched polymer (amyl pectin). The two polymers are intertwined within starch granules. Granules are insoluble in cold water, but soaking in hot water or under steam pressure -ruptures4heir a pregelatinized starch and has been used in muds for many years. Thus, pregelatinized starch is water-soluble starch that has undergone in-eversible changes by heating in water or steam. Many suitable pregelatinized starches are commercially available. For example, Master® Instant which is a pregelatinized Pea Starch with a high gel strength. Due to Its high amylases level, It has some remarkable properties. It shows an excellent stability to high temperatures, shearing and to variations in pH and is ideal for use in cold processes. A further important component is the softener, which keeps the moisture within the composition and allows to store the final product for weeks and months. It does not become hard and does not dry out. ff the mentioned meat flavoring, partially gelatinized starch and the basic component containing the active ingredient does not contain moisture one should add water during the extrusion process. This has an impact on the flexibility on the chewable veterinary compositions of the present invention. Itemed out that it is advantageous to adjust the" nfKKSture content of the product so that the final product contains water at a concentration equal to or tower than 9 % (w/w), preferably about 3 to 7 % (w/w), more preferably 4 to 6 % (w/w). For the present invention not only the proportion of meat flavoring and partially pre-gelatinized starch is extremely important but also the production process as such has an influence on the final product. The highly palatable ductile chewable veterinary composition of the present invention is the outcome of a special extrusion process. As such, extrusion is a very common thermoforming process widely used in the food industry for the production of customary feed pellets. However, in order to achieve the chewables according to the present invention, i.e. a highly palatable ductile product one has to modify the process and secure that the extradite is not heated during the rifle extrusion process because this leads to hard and crunchy products, to losses of active ingredient, and especially to a decrease of the palatabiTrty, Actually, production in the desired manner can easily be achieved. The highly palatatrfe ductile chewable veterinary composition of the present invention is conveniently carried out in an injection molding machine or extruder. A mixture comprising an effective amount of one or more ingredients that are active against animal pests, pathogens or animal –diseases Beat wavering-partially-gelatinized Frand-up-to-9 faster-is fed through the hopper onto a rotating, reciprocating screw. The material moves along the screw towards the tip. During this process, its temperature is cooled down constantly by means of oatmeal coolers around the outside of the ban-el and by the shearing action of the screw. The cooling process is controlled so that the temperature of the extradites during the whole extensions process does not exceed peak temperature of 40'C. Starting in the feeding zone and continuing in the compression zone, the extradite should not reach temperatures higher than said 40°C. It has been found that ideally the product is extruded at or near room temperature, and the extruder is cooled dove below room temperature, preferably to 5-10°C. It is then conveyed through the metering zone, where homogenization occurs, to the end of the screw. The homogenized material at the tip is then pressed through a form-determining die to obtain shaped articles of the desired size. The simplest way is cutting the extricate that leaves the ectoderm into equal pieces of the desired size. 'Desired' means that each piece contains the appropriate amount of active ingredient Thus, for example, for big dogs one would produce bigger pieces than for young cats. The amount of active tngrecBent has to be adapted to the bodyweight of the animal that has to be treated. This cooling during the extrusion process is extremely important because extruding this kirks of a material without cooling can easily lead to temperatures inside the entangler In the range of 100-200'C. High extrusion temperatures however transform the matrix of the extradites in an undesirable manner. The reason for this being that the starch is heated above the mating and glass transition temperatures of its components so that they undergo endothennic transitions. As a consequence a melting and disordering of the molecular structure of the starch granules takes place, so that an essentially destructurized starch is obtained. Instead of a ductile and rather soft product one obtains a hard or crunchy product which is not only refused by the animals but does not contain a reproducible amount of active ingredient Many active ingredients are not even stable enough at these relatively high temperatures and are at least partially degraded. As a result the biological activity of the product is reduced, and undesired degradation products can be formed that can cause undesired side effects or lead to allergic reactions. Cooling the extruder to temperatures near room temperature, preferably to 5-10**C, suppresses all these undesired effects and leads to a perfect product that is not only highly palatable but can surprisingly be stored for months without being degraded. The4w§hly-palatable-duGtile-Ghewable-veteriRary-eompesftien-ef4he- also contain a sweetener for further improving the palatability. Any natural sugar can be used including confectioners’ sugar, multifold, xylitol, orbital, manifold, lactose, dextrose, saccharine, glucose or fructose, or any mixture thereof. In addition, artificial sweeteners known in the art, including saccharin, aspartame and Aciculae-K. may also be used. The sweetener is preferably present in an amount of from 1 to 10 % (war), preferably between from about 3 to about 7 % (w/w) based on the sweetening power of sucrose. The sweetener serves as a palatability enhancer due to its organoleptic properties. Enhancement of the palatability can be especially achieved in those cases where the active ingredient is extremely bitter or exhibits a taste that is absolutely not accepted by the animal. The veterinary composition of the present invention may also contain an antioxidant even so it turned out that in most of the cases this is not necessary. However, in certain cases the antioxidant serves as a preservative that increases the stability of ingredients that are not stable if exposed for a longer period of time to oxygen. The term "antioxidant" represents the tutees groups of antioxidants, true antioxidants, such as Tendon 2, Tendon PG, Tendon s-1, BHA (24-butyM-methoxypheno!), and BHT (2,6-di-t-butyl-4-methylphenol). sodium metabisulfite reducing agents and ant oxidant synergists, such as tocopherols (alpha, beta, or delta-tocopherol. tocopherol esters, alpha-tocopherol acetate), alkyl gallants, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, eidetic acid and its salts, lecithin and tartaric acid. Further suitable antioxidants are reservation, quartering, benzoic acid, Trolled (N-acetylcysteine, 6-hydroxy-2,5.7,8-tetramethylchroman-2-cartDOxylic acid), dim ethyl theory (DMTU), desperation, tetrahydrocurcumin. tetrahydrodemethoxycurcumin, and monothioglycerol. Said antioxidant being added in concentrations ranging from 0 to 3.5 % (war), preferably 0.01 to 0.5 % (w/w). Preferred antioxidant are Tenox 2 and BHA (2-t-butyl-4-methoxyphenoI). Sodium chloride may also be added, up to about 4% (w/w), to further improve the palatability of the product and to bind moisture. For certain animals sodium chloride serves like a palatability enhancer. The highly palatable ductile chewable veterinary composition of the present invention further may contain a softener. The softener for use in the invention serves as a humectants which enhance s-toe-flexibility- ehew-aiid-retaiBSHT oyster chew is maintained at ambient temperatures. Typically, the softener is present in the highly palatable ductile chewable veterinary composition of the present invention at concentrations from about 10-20 % (w/w) and preferably about 11-15% (w/w) based upon the weight of the partially gelatinized starch. Suitable softeners include alcohols such as orbital, manioc, hexapod, pentagon and polo’s (such as glycerin, propylene glycol, polyethylene glycol, and polypropylene glycol). The highly palatable ductile chewable veterinary composition of the present invention may further contain a coloring agent that lead to a better-looking product. The coloring agent can be selected from the group of azo dyes, organic or inorganic pigments, or coloring agents of natural origin, preferably from oxides of iron of titanium. Said coloring agent being added in concentrations ranging from 0 to 5 % (w/w), preferably 0.05 to 2 % (w/w). A preferred coloring agent is fennec oxide, that is normally used in an amount amour 0.1 % (w/w). Technical Equipment The extruder used for the production of the chewables according to the present invention is a co-rotating twin screw extruder type BCTG-62/28D with a diameter of 62 mm and a screw length of L/D ratio of 28D with a polluting device from Buhler AG; Industriestrasse; CH-9240 Uzi; Switzerland. The feeder (delivering the dry blend into the extruder) is obtainable from K-Tran, Switzerland. It is a loss in weight feeder type K2-ML-T 35 twin screw feeder equipped with a AC (twin auger) screw. In addition two pumps are use to deliver glycerin and water separately. In addition, two chillers are used to maintain an extruder temperature below 10°C. Measurement of the softness/hardness of the chewables The texture (softness/hardness) of the dewy is measured by using a TEXTURE ANALYSER type; TA-XT2 iHR/25 that is commercially available from Stable Micro Systems Ltd. (Headquarters: Stable Micro Systems Ltd., Vienna Court, Lames Road; UK). One measures the peak force (in N) necessary to push a sphere with a melody of 1 mm/sec to penetrate 2mm into the chewable. The sphere has a diameter of 8 mm. The texture of the •chewables is measured-to-determine- before they are packaged into blisters. Texture after 24 hours: Typical values lay between 8 and 20 N. Examples Examine 1: 2-Wav-formulatiQn containing Milbemvcin oxime and Praziquantel Ingredients Amount Percentage [w/w] Active ingredient No.1 MBbemydn oxide 1-975 kg 0.395% Active in Client No. 2 Praziquantel 19.000 kg 3.800% Endpoints Pre-galvanized starch 205.025 kg 41.005% Natural chicken flavor 150.000 kg 30.000% Sugar 25.000 kg 5,000% Sodium chloride powder 7.500 kg 1.500% Fenwick oxide 0.500 kg 0,100% Total solids 409.000 kg 81.800% Water 20.000 kg 4.000 % Glycerin 70.000 kg 14.000% Tenox 2 1,000 kg 0.200% Total liquids 91.000 kg 18.200% Total batch size 500.000 kg 100.000% The 2-Way-formulat!on containing Milbemycin oxide and Praziquantel is produced as follows: 1-. - Pre=nod-WfflbenTycin^x3xinTC-(ir9f5i^ gelatinized Starch using a V-blender for 5 min. 2. Vacuum transfer through a 10 mesh screen into a bin blender 3. Vacuum transfer praziquantel, confectionery sugar, sodium chloride, chicken flavor and the rest of pregelatinized starch through a 10 mesh screen into a bin blender and blend for 20 min 4. Weigh water into the water tank and weigh glycerin into the glycerin tank and mix with tenox. 5. Start extruder: 6. Cooling unit temperature is set at S'^C 7. Dry blend (mixture of step 3) is fed into BCTG extruder through K-torn feeding device. 8. Glycerin/Tenox 2 mixture is pumped into the extender 9. Water is pumped into the extenders 10. Extenders velocity (rpm) is adjusted according feeding velocity of the dry blend 11. Cutting device of the extruder is adjusted to get the appropriate weights of the chewables 1Z After extrusion the chewables are transported via conveyer to a hopping conveyer and- finally 13. Riled into boxes of not more than 3 inches 14. Curing of the chewables for approx. 24 hours at ambient temperature and relative humidity 15. After curing chewables are packaged into blister packages Example 2: 3-Wav-formulation containing Milbemvcin oxides. Praziquantel and Lufenuron Ingredients *Antoine ' Percentage [waive] Active ingredient No. 1 1.975 kg 0.395% Milbemycin oxide Active ingredient No. 2 19.000 kg 3.800% Praziquantel Active ingredient No. 3 38.340 kg 7.667 % Lufenuron Recipients Pre-gelatinized starch 159.690 kg 31.938% Powdered Cooked Beef 142.000 kg 30.000% Stock Aid Bacon Razor 25.000 kg 5.000% Sugar 25.000 kg 5.000% Sodium chloride powder 7.500 kg 1.500% Ferric oxide 0.500 kg 0.100% Total solids 419.000 kg 83.800% Water 20.000 kg'- "4.000% Lykens 60.000 kg 12.000% Teri ox2 1.000 kg 0.200% Total Squids 81.000 kg 16.200% Total batch size 500.000 kg 100.000% The 3-Way-formuiation containing Milbemycin oxide, Praziquantel and Lufenuron is produced along the same lines as described for the 2-Way-formulation in Example 1. Example 3: 1-Wav-formulation containing Cyclosporin Ingredients Amount Percentage [w/w] Active ingredient Cyclosporin 43.40 g 8.7% Pre-gelatinized starch 183.60 g 36.7% Natural chicken flavor 150.00 g 30.0% Sugar 25.0 g 5.0 % Ferric oxlip 0.50 g 0.1% Tote-solids 41^70G-g - -82:0%- Water 20.00 g 4.0 % Glycerin 70.00 g 14.0% Total liquids 90.00 g 18.0% Total batch size 500.00 g 100.00% The 1-Way-formulation containing Cyclostomes is produced along the same lines as described for the 2-Way-formulation in Example 1. Example 4: Palatabil'rtv (acceptance) test for different flavored chewables of a 3-wav formulation with 100 dogs and 100 cats 100 male and female dogs of different breeds and age are tested. The dogs are divided in 4 groups of 25 dogs of the same bodyweight. The testing person offers once a day to each dog one test-chewable which is adapted to the bodyweight of the dog. In a first instance the chewable is offered by hand for 60 seconds. If the dog does not take the formulation it is offered the dog in his empty bowl, the dog has again 60 seconds to take the formulations, if writ, ft is paced in his/her mouth. If ties dog/cat spits It out it is reported as not accepted. In general not more than 5 to 6 different fornications are tested on consecutive days. Each formulation Is packaged separately and labeled so that they can be clearly identified. An analogous test is carried out with 100 cats. Example 5: Stability tests Samples of the toughly palatable ductile chewable veterinary composition of the preset invention are tested for stability under stressing conditions in order to simulate different temp Buttes and humidity conditions. The samples are tested at 25°C/60 rhea, 30°C 60% rah awry 40' 75%rh. They are kept in incubators' and are analyzed after 3, 6. 9 and 12 months with regard to active ingredient content. The analyze of the content of active ingredient of all samples tested at 25X/60 try and 30 60% rhea for 12 months show no difference" in'^ comparison with identical samples kept in the refrigerator at - 25°C for the same period of time. Chewables kept 12 months at 40'*C/75%rh show also good stability results which infected that they would lead to a shelf live for at least 12 monotints if stored under normal conditions, i.e. 25or 30°C and 40-70% rhea. No significant difference is seen with regard to the stalwarts of 2-way-formulations containing Milbemycin oxide and Praziquantel and 3-way-formulation containing Milbemycin oxide, Praziquantel and Lufenuron. CLAIMS What is claimed is: 1. A highly palatable ductile chewable veterinary composition comprising (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener, and (E) up to 9% water. 2. A chewable veterinary composition according to claim 1 wherein the animal disease comprises viral or bacterial infections, behavioral disorders, inflammatory diseases, and auto-immune diseases. 3. A chewable veterinary composition according to claim 1 comprising 20 to 30 % (w/w) of a natural meat flavoring. 4. A chewable veterinary composition according to claim 4 wherein the natural meat flavoring comprises 20 to 55 % (w/w) fat. 5. A chewable veterinary composition according to claim 1 comprising 25 to 70 % (w/w) of partially gelatinized starch. 6. A chewable veterinary composition according to claim 5 wherein the partially gelatinized starch comprises 12 to 17 % (w/w) of gelatinized starch. Z.nA^ev\^ble4/eteriRary-^^mposifion-aGGOi:ding4o-dai?TM^ %_(AV/W)-O^ softener, based upon the weight of the partially gelatinized starch. 8. A chewable veterinary composition according to claim 7 wherein the softener is selected from the group consisting of glycerol, polyethylene glycol and polypropylene glycol. 9. A chewable veterinary composition according to claim 1 comprising 4 to 6 % (w/w) of water. 10. A chewable veterinary composition according to claim 1 wherein the animal pests are external animal parasites or internal animal parasites or both. 11. A chewable veterinary composition according to claim 1 comprising 1 to 10 % (w/w) of a sweeter>er- 12. A chewable veterinary composition according to claim 1 comprising 0 to 3.5 % (w/w) of an arrtioxidanL 13. A chewable veterinary composition according to claim 1 comprising 0 to 5 % (w/w) of a coloring agent 14. A chewable veterinary composition according to claim 1 comprising 0 to 4% (w/w) of sodium chloride. 15. A chewable veterinary composition according to claim 1 comprising an parasitic dally effective amount of an ecto-parasiticide, an endo-parasiticide, an insecticides or of a combination of a parasitoids selected from the group consisting of an ecto-parasiticide, an endo-parasftidde and an insecticide. 16. A dewater veterinary composition according to claim 15 wherein the ecto-parasiticide is active against insects, members of the order Aquarian or insects and members of the order Acarina. 17. A chewable veterinary composition according to claim 16 wherein the ecto-parasiticide is a4nsectidde-whicb4s-either- n-insert- sulfides-or nse€t-gro 18. A chewable veterinary composition according to claim 15 comprising an parasitic dally effective amount of an endo-parasiticide or insecticide selected from the group consisting of macrocodes lad ones, benzimidazoles, pro-benzimidazoles , imidazothiazoles. tetrahydropyrimidines, organophosphates and piperazines. 19. A chewable veterinary composition according to claim 18 comprising an effusive amount of a natural or chemically modified macrocodes lactose of formula (I) FU is hydroxyl. -NH-CH3 or-NH-Lochs; R2 is hydrogen. -CH3. -C2H5, -CHCCHaVCHs, -CH(CH3}-C2H5. -C(CH3)=CH-CH(CH3)2 or cyclohexyl; and to the bond between atoms 22 and 23 represents a double bond the carbon atom in 23-position is unsubstituted so that Y is =C(H)-. or if is the bond between atoms 22 and 23 is a single bond the carbon atom in 23-position is unsubstituted or substituted by hydroxy or by the group =N-0-CH3 so that Y Is -C(H2)-; -C(H)(OH)-; or -C(=N-0CH3)-; in free front or in the fond of a physiologically sally _ 20. A chewable veterinary composition according to claim 19 wherein the macro cyclic lactones is a compound of the formula (I) wherein X is -C(H)(OH)-; Y is -C(H2)-; Rip is the radical R2 is -CH3 or C2H5, and the bond between atoms 22 and 23 represents a single bond. 21. A chewable veterinary composition according to claim 19 wherein the macro cyclic lactones is selected from the group consisting of avermectins, milbemycins and derivatives thereof, in free form or in the form of a physiologically acceptable salt 22. A chewable veterinary composition according to claim 21 wherein the macro cyclic lactones is selected from the group consisting of Ivermectin, Doramectin,- Moxidectin, Seat elfin, Emamectin. Eprinomectin. Milbemectin. J amercing, Milbemycin oxide, Nonaddicting, and a derivative thereof, in free form or in the form of a physiologically acceptable salt 23. A viewable veterinary composition according to claim 18 comprising an effective amount of a macro cyclic lactones in combination with an effective amount of an anathematic selected from the group consisting of Albendazole, Corpulent, Cadetting, Diethylcarbamazine, Debated. Fenbendazole, Saloon, Levamisole. Mebendazole, Mordant, Oxyclozanide, Owbendazole, Oxfendazole, Oxfendazole, Oxamniquine, Pirates, Pauperizing, Praziquantel, Thiabendazole. Tetramisole. Trichlorfon, Thiabendazole, and a derivative thereof, 24. A Viewable veterinary composition according to claim 18 comprising additionally an effective amount of an insecticide, acaroids or an insecticide and an acaroids. 25. A chewable veterinary composition according to claim 1 comprising an effective amount of mflbemycin owes and praziquantel. 27. A chewable veterinary composition according to claim 1 comprising an effective amount of cyclosporin, 28. A chewable veterinary composition according to claim 1 comprising an effective amount of an antimicrobial selected from the group consisting of a penicillin, tetracycline, sulfonamide, cephalosporin, cephamycln, aminoglucosid, trimethoprim, dimetridazole. erytiiromycin, framycetin, fruazolidone, pleuromutilin, streptomycin and a compound that is active against protozoa. 29. A chewable veterinary composition according to claim 1 comprising an effective amount of compound that is active against behavioral including separation won or travel sockeyes of cots and cats. 30. Process for the production of a highly palatable ductile chewable "veterinary composition of daim 1, comprising (i) feeding the hoof of an extruder with an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; n eat flavoring; partially gelatinized starch; a softener; and up to 9% (w/w) of water, (it cooling constantly down the mixture of active ingredients and carriers so that the temperature of the extrudate that leaves the tip of the extruder does during the whole extrusion process at no time exceed 40 C, (iii) pressing the extrudate through a die that is decisive for the shape of the chewable product, and (iv) cutting the extrudate that leaves the extruder into equal pieces. 31 Process according to claim 30 wherein the hopper of the extruder is fed continuously and simultaneously with pre-mixture (1) and pre-mixture (2), wherein pre-mixture (1) consist of a homogenized mixture of one or more active ingredients and partially gelatinized starch, and pre-mixture (2) consists of a homogenized mixture of meat flavoring, a softener and optionally of a carrier selected from the group consisting of a sweetener, softener, an antioxidant, a coloring agent and sodium chloride. 32. Process according to claim 30 wherein the extruder is cooled down below room temperature, 33. Method of controlling nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases comprising feeding an animal with a palatable ductile chewable veterinary composition according to claim 1. 34. Method according to claim 33, wherein the palatable ductile chewable veterinary composition consist of one chewable portion containing an effective amount of a compound or mixture of compounds capable of controlling nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases. 35. Method according to claim 34 wherein the amount of active ingredient is adjusted to the bodyweight of the nonhuman animal that is in need of the treatment. 36. Use of (A) an effusive amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener (E) up to 9% water, and an active ingredient suitable for combating animal pests, pathogens or animal diseases for the preparation of a highly palatable ductile chewable veterinary composition. 37. Use according to claim 36 comprising 20 to 30 % (w/w) of a natural meat flavoring. 38. Use according to claim 37 wherein the natural meat flavoring comprises 20 to 55 % (w/w) fat. 39. Use according to claim 36 comprising 25 to 70 % (w/w) of partially gelatinized starch. 40. Use according to claim 39 wherein the partially gelatinized starch comprises 12 to 17 % (w/w) of gelatinized starch. 41 Use according to claim 26 comprising 10 to 20 % (w/w) of a softener, based upon the weight of the partially gelatinized starch. 4? Use according tn claiiTL4iIwbeiBiD-tba softener is. selected fnom-tbe-groupxoDsisting^f glycerol, polyethylene glycol and polypropylene glycol. 43. Use according to claim 36 comprising 3 to 7 % (w/w) of water. 44. Use according to claim 36 wherein the animal pests are external animal parasites or internal animal parasites or both. 45. Use according to claim 36 comprising 1 to 10 % (w/w) of a sweetener. 46. Use according to claim 36 comprising 0 to 3.5 % (w/w) of an antioxidant. 47. Use according to claim 36 comprising 0 to 5 % (w/w) of a coloring agent. 48. Use according to claim 36 comprising 0 to 4% (w/w) of sodium chloride. 49. Use according-to claim 36 comprising an parasiticidaliy effective amount of an edo-parasftidde, an endo-parasiticide, an insecticide or of a combination of a parasitoids selected from the group consisting of an ecto-parasiticide, an endo-parasiticide and an insecticide. 50. Use according to claim 36 wherein the ecto-parasiticide is active against insects, members of the order Acadian or insects and members of the order Aquarian. 51 Use according to claim 36 wherein the ecto-parasiticide is an insecticide which is either an insect adulticides or insect growth regulators. 52. Use according to claim 36 comprising an parasiticidaliy effective amount of an endo-parasiticide or endecticide selected from the group consisting of macrocyclic lactones, benzimidazoles. pro-benzimidazoles , imidazothiazoles, tetrahydropyrimidines, organophosphates and piperazines. 53. Use according to claim 36 comprising an effective amount of a natural or chemically modified macrocyclic lactone of formula (I) wherein X is -C(H)(OH)-; -C(0)-; or-C(=N-OH)-; Y is -C(H2)- ; =C(H)-; -C{H)(OH)- ; or-C(=N-OCH3)-; Ri is hydrogen or one of radicals R4 is hydroxyl, -NH-CH3 or -NH-OCH3; R2 is hydrogen. -CH3, -C2H5, -CH(CH3)-CH3. -CH(CH3>-C2H5, -C(CH3)=CH-CH(CH3)2 or cyclohexyl; and if the bond between atoms 22 and 23 represents a double bond the carbon atom in 23-position is unsubstituted so that Y is =C(H)-. or if is the bond between atoms 22 and 23 is a single bond the carbon atom in 23-position is unsubstituted or substituted by hydroxy or by the group =N-0-CH3 so that Y is -C(H2)-; -C(H)(OH>-; or-C(=N-OCH3)-; in free form or in the form of a physiologically acceptable salt. 54. Use according to claim 53 wherein the macrocyclic lactone is a compound of the formula (I) wherein X is -C(H)(OH)-; Y is -C{H2)s R1 is the radical R2 is -CH3 or C2H5. and the bond between atoms 22 and 23 represents a single bond. 55. Use according to claim 49 wherein the endecticide is a macrocyclic lactone is selected from the group consisting of avemiectins, milbemycins and derivatives thereof, in free form or in the fungi of a physiologically acceptable salt, 56. Use according to claim 53 wherein the macrocyclic lactone is selected from the group consisting of Ivermectin, Doramectin, Moxidectin, Selamectin, Emamectin, Eprinomectin, Milbemectin, Abamectin. Milbemycin oxeye, Nonaddicting, and a derivative thereof, in free fond or in the form of a physiologically acceptable salt. 57. Use according to claim 49 comprising an effective amount of a macrocyclic lactone in combination with an effective amount of an antiielmintic selected from tiles group consisting of Albendazole, Corpulent, Cadetting, Dietliylcarbamazine. Debate, Fenbendazole, Halo on, Levamisole, Mebendazole, Ornate, Oxyclozanide, Oxibendazole, Oxfendazole, Oxfendazole, Oxamniquine, Prattle, Pauperizing, Praziquantel, Thiabendazole, Tetramisole. Trichlorfon, Thiabendazole, and a derivative thereof. 58. Use according to claim 49 comprising in addition to an endo-parasiticide or an endecticide an effective amount of an insecticide, accuracies or an insecticide and an acaridae, 59. Use according to claim 36 comprising an effective amount of milbemycin oxime and praziquantel. 60. Use according to claim 36 comprising an effective amount of lufenuron, praziquantel and milbemycin oxime. 61. Use according to claim 36 comprising an effective amount of cyclosporin. 62. Use according to claim 36 comprising an effective amount of an antimicrobial selected from the group consisting of a penicillin, tetracycline, sulfonamide, cephalosporin, cephamycin, aminoglucosid. trimethoprim, dimetridazole, erythromycin, framycetin, fruazolidone. pleuromutilin, streptomycin and a compound that is active against protozoa, 63. Use according to claim 36 comprising an effective amount of compound that is active _ against behavioral including separation worry ornately sickaess-oLdogs-apd-cats 64. Use of a highly palatable ductile chewable veterinary composition of claim 1 in a process of controlling nonhuman animal pests or nonhuman animal pathogens or of curing or preventing nonhuman animals diseases. |
|---|
382-chenp-2006-correspondnece-others.pdf
382-chenp-2006-correspondnece-po.pdf
382-chenp-2006-description(complete).pdf
| Patent Number | 229998 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 382/CHENP/2006 | ||||||||
| PG Journal Number | 13/2009 | ||||||||
| Publication Date | 27-Mar-2009 | ||||||||
| Grant Date | 24-Feb-2009 | ||||||||
| Date of Filing | 30-Jan-2006 | ||||||||
| Name of Patentee | NOVARTIS AG | ||||||||
| Applicant Address | Lichtstrasse 35, CH-4056 Basel, | ||||||||
Inventors:
|
|||||||||
| PCT International Classification Number | A23K1/18 | ||||||||
| PCT International Application Number | PCT/EP2004/008538 | ||||||||
| PCT International Filing date | 2004-07-29 | ||||||||
PCT Conventions:
|
|||||||||